

RECEIVED
CENTRAL FAX CENTER
Official EC 0 5 2003
OFFICIAL

AstraZeneca Docket No. 100507-1

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: Edward Pierson
Application Number: 10/051,776
Filed: 01/16/2002
For: Therapeutic Heterocyclic Compounds

Group Art Unit: 1624
Examiner: Patel, Sudhaker B

Assistant Commissioner for Patents
Washington, DC 20231

Response

Sir:

This is a response to a restriction requirement dated March 9, 2003 in which the Examiner requires Election/Restriction of the claims of this application.

Applicants hereby elect Group VI, Claim 1, with traverse, for examination in this application.

Applicants hereby elect the species of 6-fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-propionyl-piperazin-1-yl)-phenyl]-amide as the basis for a generic concept to be identified by the Examiner.

CERTIFICATE OF FACSIMILE TRANSMISSION (37 C.F.R. § 1.8)

The undersigned hereby certifies that the attached papers and/or fee are being facsimile transmitted to the United States Patent and Trademark Office at the telephone number shown below on the date shown below.

Facsimile number: 1-703-308-4556

Date: Dec 5, 2003

George Gilbert
Reg. No. 35,881

Signature 